Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed
Data supported both once every two week and once every four week maintenance dosing, with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 7, 2022 Category: Pharmaceuticals Source Type: clinical trials
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key secondary endpoints
INDIANAPOLIS, April 11, 2022... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 11, 2022 Category: Pharmaceuticals Source Type: clinical trials
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
Lebrikizumab rapidly improved skin and itch symptoms in four weeks
INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 26, 2022 Category: Pharmaceuticals Source Type: clinical trials
SOOTHER Trial to Treat Rectal Itch
Condition: Pruritus Ani Intervention: Drug: Lidocaine Ointment Sponsor: Bell International Laboratories Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2022 Category: Research Source Type: clinical trials
